Evommune, Inc.(EVMN)
$8.62+0.78 (+9.95%)
EVMN
Evommune, Inc. financials statements
$8.62
At close:+0.78 (+9.95%)
Want to see EVMN full AI Analyst Report?
Evommune, Inc. (EVMN) Ratios
140 Followers
Evommune, Inc. Ratios
EVMN's free cash flow for Q2 2026 was $-20.50M. For the 2026 fiscal year, EVMN's free cash flow was decreased by $-183.00K and operating cash flow was $-20.32M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| Liquidity Ratios | |||
| Current Ratio | 8.57 | 2.64 | 11.67 |
| Quick Ratio | 8.57 | 2.64 | 11.67 |
| Cash Ratio | 2.46 | 0.58 | 4.23 |
| Solvency Ratio | -3.48 | -0.30 | -0.21 |
| Operating Cash Flow Ratio | -4.27 | -2.08 | -4.37 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -57.17 | -38.97 |
| Net Current Asset Value | $ 134.10M | $ -146.30M | $ -79.93M |
| Leverage Ratios | |||
| Debt-to-Assets Ratio | 0.01 | 2.54 | 1.83 |
| Debt-to-Equity Ratio | 0.01 | -1.34 | -1.94 |
| Debt-to-Capital Ratio | 0.01 | 3.94 | 2.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 4.03 | 2.08 |
| Financial Leverage Ratio | 1.09 | -0.53 | -1.06 |
| Debt Service Coverage Ratio | 0.00 | -62.25 | -39.90 |
| Interest Coverage Ratio | 0.00 | -2059.21 | -652.59 |
| Debt to Market Cap | 0.00 | 0.32 | 0.25 |
| Interest Debt Per Share | 0.28 | 6.43 | 5.01 |
| Net Debt to EBITDA | 0.53 | -2.70 | -3.69 |
| Profitability Margins | |||
| Gross Profit Margin | 100.00% | 81.61% | 80.00% |
| EBIT Margin | -623.62% | -953.91% | -679.90% |
| EBITDA Margin | -612.94% | -935.53% | -659.90% |
| Operating Profit Margin | -623.62% | -1000.19% | -757.00% |
| Pretax Profit Margin | -529.77% | -954.40% | -681.06% |
| Net Profit Margin | -529.77% | -954.40% | -681.06% |
| Continuous Operations Profit Margin | -529.77% | -954.40% | -681.06% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 84.95% | 95.42% | 89.97% |
| Return on Assets (ROA) | -30.62% | -87.84% | -41.40% |
| Return on Equity (ROE) | -33.50% | 46.32% | 43.82% |
| Return on Capital Employed (ROCE) | -39.16% | -145.64% | -50.20% |
| Return on Invested Capital (ROIC) | -39.11% | -142.62% | -49.70% |
| Return on Tangible Assets | -30.62% | -87.84% | -41.40% |
| Earnings Yield | -65.55% | -10.98% | -5.60% |
| Efficiency Ratios | |||
| Receivables Turnover | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.16 | 0.57 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 5.28 | 3.89 | 2.54 |
| Asset Turnover | 0.06 | 0.09 | 0.06 |
| Working Capital Turnover Ratio | 0.14 | 0.12 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2343.71 | -641.67 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2343.71 | 641.67 |
| Operating Cycle | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||
| Operating Cash Flow Per Share | -12.46 | -1.93 | -1.00 |
| Free Cash Flow Per Share | -12.49 | -1.94 | -1.00 |
| Dividend Paid and CapEx Coverage Ratio | -325.28 | -661.31 | -253.98 |
| Capital Expenditure Coverage Ratio | -325.28 | -661.31 | -253.98 |
| Operating Cash Flow Coverage Ratio | -44.62 | -0.30 | -0.20 |
| Operating Cash Flow to Sales Ratio | -5.88 | -8.31 | -5.99 |
| Free Cash Flow Yield | -72.98% | -9.58% | -4.94% |
| Valuation Ratios | |||
| Price-to-Earnings (P/E) Ratio | -1.53 | -8.91 | -17.87 |
| Price-to-Sales (P/S) Ratio | 8.08 | 86.92 | 121.69 |
| Price-to-Book (P/B) Ratio | 0.51 | -4.22 | -7.83 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.37 | -10.44 | -20.22 |
| Price-to-Operating Cash Flow Ratio | -1.37 | -10.46 | -20.30 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.09 | 0.00 |
| Enterprise Value Multiple | -0.79 | -12.00 | -22.13 |
| Enterprise Value | 62.71M | 785.53M | 730.08M |
| EV to EBITDA | -0.79 | -12.00 | -22.13 |
| EV to Sales | 4.82 | 112.22 | 146.02 |
| EV to Free Cash Flow | -0.82 | -13.48 | -24.26 |
| EV to Operating Cash Flow | -0.82 | -13.50 | -24.36 |
| Tangible Book Value Per Share | 33.50 | -4.80 | -2.58 |
| Shareholders’ Equity Per Share | 33.50 | -4.80 | -2.58 |
| Tax and Other Ratios | |||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.12 | 0.23 | 0.17 |
| Net Income Per Share | -11.22 | -2.22 | -1.13 |
| Tax Burden | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.85 | 1.00 | 1.00 |
| Research & Development to Revenue | 5.70 | 9.18 | 6.40 |
| SG&A to Revenue | 1.54 | 1.64 | 0.00 |
| Stock-Based Compensation to Revenue | 0.45 | 0.00 | 0.00 |
| Income Quality | 1.11 | 0.87 | 0.88 |
Currency in USD
